OCUL

Company Overview — What Does OCULAR THERAPEUTIX, INC Do?

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. OCULAR THERAPEUTIX, INC (OCUL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Antony Mattessich and employs approximately 230 people, headquartered in BEDFORD, Massachusetts. With a market capitalization of $1.8B, OCUL is one of the notable companies in the Healthcare sector.

OCULAR THERAPEUTIX, INC (OCUL) Stock Rating — Avoid (April 2026)

As of April 2026, OCULAR THERAPEUTIX, INC receives a Avoid rating with a composite score of 30.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.OCUL ranks #4,185 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, OCULAR THERAPEUTIX, INC ranks #746 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OCUL Stock Price and 52-Week Range

OCULAR THERAPEUTIX, INC (OCUL) currently trades at $8.84. The stock lost $0.46 (4.9%) in the most recent trading session. The 52-week high for OCUL is $16.44, which means the stock is currently trading -46.2% from its annual peak. The 52-week low is $5.80, putting the stock 52.4% above its annual trough. Recent trading volume was 3.1M shares, reflecting moderate market activity.

Is OCUL Overvalued or Undervalued? — Valuation Analysis

OCULAR THERAPEUTIX, INC (OCUL) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.77x, versus the sector average of 2.75x. The price-to-sales ratio is 33.54x, compared to 1.66x for the average Healthcare stock.

At current multiples, OCULAR THERAPEUTIX, INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

OCULAR THERAPEUTIX, INC Profitability — ROE, Margins, and Quality Score

OCULAR THERAPEUTIX, INC (OCUL) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -36.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -29.4% versus the sector average of -33.1%.

On a margin basis, OCULAR THERAPEUTIX, INC reports gross margins of 87.9%, compared to 71.5% for the sector. The operating margin is -467.6% (sector: -66.1%). Net profit margin stands at -454.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -11.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OCUL Debt, Balance Sheet, and Financial Health

OCULAR THERAPEUTIX, INC has a debt-to-equity ratio of 23.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 15.39x, indicating strong short-term liquidity. Total debt on the balance sheet is $71M. Cash and equivalents stand at $345M.

OCUL has a beta of 1.25, meaning it is more volatile than the broader market — a $10,000 investment in OCUL would be expected to move 24.9% more than the S&P 500 on any given day. The stability factor score for OCULAR THERAPEUTIX, INC is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

OCULAR THERAPEUTIX, INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, OCULAR THERAPEUTIX, INC reported revenue of $54M and earnings per share (EPS) of $-1.42. Net income for the quarter was $-238M. Gross margin was 87.9%. Operating income came in at $-246M.

In FY 2025, OCULAR THERAPEUTIX, INC reported revenue of $52M and earnings per share (EPS) of $-1.42. Net income for the quarter was $-266M. Gross margin was 87.4%. Revenue grew -18.5% year-over-year compared to FY 2024. Operating income came in at $-270M.

In Q3 2025, OCULAR THERAPEUTIX, INC reported revenue of $15M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-69M. Gross margin was 87.8%. Revenue grew -5.7% year-over-year compared to Q3 2024. Operating income came in at $-69M.

In Q2 2025, OCULAR THERAPEUTIX, INC reported revenue of $13M and earnings per share (EPS) of $-0.39. Net income for the quarter was $-68M. Gross margin was 85.6%. Revenue grew -18.1% year-over-year compared to Q2 2024. Operating income came in at $-68M.

Over the past 8 quarters, OCULAR THERAPEUTIX, INC has demonstrated a growth trajectory, with revenue expanding from $16M to $54M. Investors analyzing OCUL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OCUL Dividend Yield and Income Analysis

OCULAR THERAPEUTIX, INC (OCUL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OCUL Momentum and Technical Analysis Profile

OCULAR THERAPEUTIX, INC (OCUL) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

OCUL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, OCULAR THERAPEUTIX, INC (OCUL) ranks #746 out of 838 stocks based on the Blank Capital composite score. This places OCUL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OCUL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OCUL vs S&P 500 (SPY) comparison to assess how OCULAR THERAPEUTIX, INC stacks up against the broader market across all factor dimensions.

OCUL Next Earnings Date

No upcoming earnings date has been announced for OCULAR THERAPEUTIX, INC (OCUL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OCUL? — Investment Thesis Summary

The quantitative profile for OCULAR THERAPEUTIX, INC suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. High volatility (stability score 30/100) increases portfolio risk.

In summary, OCULAR THERAPEUTIX, INC (OCUL) earns a Avoid rating with a composite score of 30.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OCUL stock.

Related Resources for OCUL Investors

Explore more research and tools: OCUL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OCUL head-to-head with peers: OCUL vs AZN, OCUL vs SLGL, OCUL vs VMD.